|
1
|
Ampil FL, Ghali GE, Caldito G and Hardin
JC Jr: Treatment of head and neck cancer with bone or cartilage
invasion by surgery and postoperative radiotherapy. J Oral
Maxillofac Surg. 62:408–411. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shimo T and Sasaki A: Mechanism of
cancer-induced bone destruction: An association of connective
tissue growth factor (CTGF/CCN2) in the bone metastasis. Jpn Dent
Sci Rev. 47:13–22. 2011. View Article : Google Scholar
|
|
3
|
Weilbaecher KN, Guise TA and McCauley LK:
Cancer to bone: A fatal attraction. Nat Rev Cancer. 11:411–425.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shimo T, Kubota S, Yoshioka N, Ibaragi S,
Isowa S, Eguchi T, Sasaki A and Takigawa M: Pathogenic role of
connective tissue growth factor (CTGF/CCN2) in osteolytic
metastasis of breast cancer. J Bone Miner Res. 21:1045–1059. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luo Y, Raible D and Raper JA: Collapsin: A
protein in brain that induces the collapse and paralysis of
neuronal growth cones. Cell. 75:217–227. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kolodkin AL, Matthes DJ and Goodman CS:
The semaphorin genes encode a family of transmembrane and secreted
growth cone guidance molecules. Cell. 75:1389–1399. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang YH, Buhamrah A, Schneider A, Lin YL,
Zhou H, Bugshan A and Basile JR: Semaphorin 4D promotes skeletal
metastasis in breast cancer. PLoS One. 11:e01501512016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Epstein JA, Aghajanian H and Singh MK:
Semaphorin signaling in cardiovascular development. Cell Metab.
21:163–173. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Messina A and Giacobini P: Semaphorin
signaling in the development and function of the gonadotropin
hormone-releasing hormone system. Front Endocrinol (Lausanne).
4:1332013.
|
|
10
|
Kang S, Okuno T, Takegahara N, Takamatsu
H, Nojima S, Kimura T, Yoshida Y, Ito D, Ohmae S, You DJ, et al:
Intestinal epithelial cell-derived semaphorin 7A negatively
regulates development of colitis via αvβ1 integrin. J Immunol.
188:1108–1116. 2012. View Article : Google Scholar
|
|
11
|
Mizui M, Kumanogoh A and Kikutani H:
Immune semaphorins: Novel features of neural guidance molecules. J
Clin Immunol. 29:1–11. 2009. View Article : Google Scholar
|
|
12
|
Shanks K, Nkyimbeng-Takwi EH, Smith E,
Lipsky MM, DeTolla LJ, Scott DW, Keegan AD and Chapoval SP:
Neuroimmune semaphorin 4D is necessary for optimal lung allergic
inflammation. Mol Immunol. 56:480–487. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moreau-Fauvarque C, Kumanogoh A, Camand E,
Jaillard C, Barbin G, Boquet I, Love C, Jones EY, Kikutani H,
Lubetzki C, et al: The transmembrane semaphorin Sema4D/CD100, an
inhibitor of axonal growth, is expressed on oligodendrocytes and
upregulated after CNS lesion. J Neurosci. 23:9229–9239.
2003.PubMed/NCBI
|
|
14
|
Negishi-Koga T, Shinohara M, Komatsu N,
Bito H, Kodama T, Friedel RH and Takayanagi H: Suppression of bone
formation by osteoclastic expression of semaphorin 4D. Nat Med.
17:1473–1480. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Basile JR, Castilho RM, Williams VP and
Gutkind JS: Semaphorin 4D provides a link between axon guidance
processes and tumor-induced angiogenesis. Proc Natl Acad Sci USA.
103:9017–9022. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shimo T, Matsumoto K, Takabatake K, Aoyama
E, Takebe Y, Ibaragi S, Okui T, Kurio N, Takada H, Obata K, et al:
The role of sonic hedgehog signaling in osteoclastogenesis and jaw
bone destruction. PLoS One. 11:e01517312016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goda T, Shimo T, Yoshihama Y, Hassan NM,
Ibaragi S, Kurio N, Okui T, Honami T, Kishimoto K and Sasaki A:
Bone destruction by invading oral squamous carcinoma cells mediated
by the transforming growth factor-beta signalling pathway.
Anticancer Res. 30:2615–2623. 2010.PubMed/NCBI
|
|
18
|
Kuroda Y, Hisatsune C, Nakamura T, Matsuo
K and Mikoshiba K: Osteoblasts induce Ca2+
oscillation-independent NFATc1 activation during
osteoclastogenesis. Proc Natl Acad Sci USA. 105:8643–8648. 2008.
View Article : Google Scholar
|
|
19
|
Sakurai A, Doçi CL and Gutkind JS:
Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer.
Cell Res. 22:23–32. 2012. View Article : Google Scholar :
|
|
20
|
Swiercz JM, Worzfeld T and Offermanns S:
ErbB-2 and met reciprocally regulate cellular signaling via
plexin-B1. J Biol Chem. 283:1893–1901. 2008. View Article : Google Scholar
|
|
21
|
Worzfeld T, Swiercz JM, Looso M, Straub
BK, Sivaraj KK and Offermanns S: ErbB-2 signals through Plexin-B1
to promote breast cancer metastasis. J Clin Invest. 122:1296–1305.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ye S, Hao X, Zhou T, Wu M, Wei J, Wang Y,
Zhou L, Jiang X, Ji L, Chen Y, et al: Plexin-B1 silencing inhibits
ovarian cancer cell migration and invasion. BMC Cancer. 10:6112010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Capparuccia L and Tamagnone L: Semaphorin
signaling in cancer cells and in cells of the tumor
microenvironment - two sides of a coin. J Cell Sci. 122:1723–1736.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Basile JR, Afkhami T and Gutkind JS:
Semaphorin 4D/plexin-B1 induces endothelial cell migration through
the activation of PYK2, Src, and the phosphatidylinositol
3-kinase-Akt pathway. Mol Cell Biol. 25:6889–6898. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aurandt J, Li W and Guan K-L: Semaphorin
4D activates the MAPK pathway downstream of plexin-B1. Biochem J.
394:459–464. 2006. View Article : Google Scholar :
|
|
26
|
Kumanogoh A and Kikutani H: Immunological
functions of the neuropilins and plexins as receptors for
semaphorins. Nat Rev Immunol. 13:802–814. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dacquin R, Domenget C, Kumanogoh A,
Kikutani H, Jurdic P and Machuca-Gayet I: Control of bone
resorption by semaphorin 4D is dependent on ovarian function. PLoS
One. 6:e266272011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ressler S, Mlineritsch B and Greil R:
Zoledronic acid for adjuvant use in patients with breast cancer.
Expert Rev Anticancer Ther. 11:333–349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stopeck AT, Lipton A, Body J-J, Steger GG,
Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA,
Viniegra M, et al: Denosumab compared with zoledronic acid for the
treatment of bone metastases in patients with advanced breast
cancer: A randomized, double-blind study. J Clin Oncol.
28:5132–5139. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fizazi K, Carducci M, Smith M, Damião R,
Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, et al:
Denosumab versus zoledronic acid for treatment of bone metastases
in men with castration-resistant prostate cancer: A randomised,
double-blind study. Lancet. 377:813–822. 2011. View Article : Google Scholar : PubMed/NCBI
|
